to instantly read 150+ free stories & 250-word summaries of all our stories

History repeats itself

MedGenome has a silver bullet for TB diagnostics, but no gun

India—home to the largest number of people living with drug-resistant TB—now has a first-of-its-kind test to diagnose TB drug resistance fast and with precision. But like the two diagnostic tests before it, SPIT SEQ must now figure out how to sell to millions

17/09/19

Suraksha P

India’s 2.8 million TB patients received a rare dose of good news in August—an indigenous, more thorough and accurate test for TB

But SPIT SEQ’s path to the mass market won’t be easy. At Rs 7,500, it’s close to 10X more expensive than existing diagnostic tools like TrueNat and GeneXpert

It took TrueNat years to get approval to become part of the national TB programme. SPIT SEQ, though, is from the stable of Sequoia-funded MedGenome

With deep-pocketed backers and a huge potential market the world over, SPIT SEQ could still have a bright future

TB-final-1920x1080.jpg

August saw two major milestones for diagnosing and curing extensively drug-resistant tuberculosis, or XDR TB—the most drug-resistant of TB strains. On 14 August, the US drug regulator approved a new drug—Pretomanid—only the third new antibiotic developed to fight TB in over half a century.

Read the full story. Create a free account.

Also read our exhaustive coverage about Future of Retail, Ride Sharing and Oyo

Or subscribe. Why? Let us explain.

Already Registered?

Related stories

More stories in /Healthcare & /Reportage

See all in Healthcare & Reportage

Want to read this story for free right now? Just

Read the full story instantly.
Just enter your email address.

Also read our exhaustive coverage about Future of Retail, Ride Sharing and Oyo

Or subscribe. Why? Let us explain.

Or

By registering, you will be signed-up for an account which gives you access to a free story published once a week and archives of all our free stories. You will also receive a daily newsletter sent to your inbox. To unsubscribe, please visit the profile section in your account.

What you get

Access all free stories

228+ archived free stories, and all upcoming ones too.

Paid story summaries

Read an exclusive 200 word summary for all our paid stories.

Daily Newsletters

Our world-renowned emails, in your inbox, every day.

Or get full access to all our stories

About subscriptions

Already Registered? Login

Questions?

What is The Ken?

The Ken is a subscription-driven media site. We write one story a day (weekdays only). These stories have sharp, original insights on technology, business, science and healthcare from India.

Why do I have to sign up to read your stories?

Our stories are not free. Well, some select stories are. But, a significant part of what we write at The Ken is for subscribers only. We put in a lot of effort and resources in writing our stories and believe that you must pay for good journalism.
Hence, our three plans. 1) The annual membership
2) The free sign up
3) The recurring quarterly subscription

On journalism and why you should pay for it, if you haven’t already seen it, here’s a great explainer from John Oliver.

So, one must pay for journalism?

Yes.

How many stories will I get if I take an annual membership?

865+ stories.

And, in the free sign up?

Four stories every month.

Do I get a refund?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am not getting my daily emails. Do I have to whitelist emails from The Ken?

An added benefit of your subscription (free/paid) are the daily personalised emails. These emails, at times, might end up in your spam/junk folder due to emojis, attachments or images. In case you’re not receiving these emails, it might help to whitelist us. If the problem still persists, write to us at [email protected].

Why am I unable to access the archives?

Full and unrestricted access to our archives is a feature of our annual membership.

My payment is not going through, what can I do?

Please write to us at [email protected] detailing the payment error or queries.

See all FAQs

    See all results for Ken

    No results found for Ken.